Jane F Apperley

List of Publications by Year
in descending order

204 papers	12,872 citations	66234 42 h-index	25716 108 g-index
205 all docs	205 docs citations	205 times ranked	11017 citing authors

#	Article	IF	Citations
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	0.6	1,743
2	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211
3	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. Journal of Clinical Oncology, 2009, 27, 6041-6051.	0.8	1,188
4	Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, 1809-1820.	0.6	1,184
5	Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. Nature, 2017, 541, 81-86.	13.7	743
6	Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta. New England Journal of Medicine, 2002, 347, 481-487.	13.9	623
7	Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology, The, 2007, 8, 1018-1029.	5.1	590
8	Ponatinib efficacy and safety in Philadelphia chromosomeâ€“positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404.	0.6	392
9	Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood, 2017, 129, 1548-1556.	0.6	340
10	The effects of imatinib on pregnancy outcome. Blood, 2008, 111, 5505-5508.	0.6	328
11	Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood, 2001, 97, 1232-1240.	0.6	271
12	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	0.6	243
13	Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial. Journal of Clinical Oncology, 2009, 27, 3472-3479.	0.8	181
14	Setting Global Standards for Stem Cell Research and Clinical Translation: TheÂ2016 ISSCR Guidelines. Stem Cell Reports, 2016, 6, 787-797.	2.3	172
15	COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia, 2021, 35, 2885-2894.	3.3	153
16	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood, 2021, 138, 2031-2041.	0.6	147
17	De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematology,the, 2019, 6, e375-e383.	2.2	129
18	Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood, 2014, 123, 3574-3577.	0.6	118

#	Article	IF	Citations
19	Part II: Management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology, The, 2007, 8, 1116-1128.	5.1	101
20	The impact of dasatinib on pregnancy outcomes. American Journal of Hematology, 2015, 90, 1111-1115.	2.0	98
21	De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematology,the, 2017, 4, e310-e316.	2.2	97
22	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia, 2019, 33, 1835-1850.	3.3	97
23	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood, 2021, 138, 2042-2050.	0.6	95
24	Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 2016, 101, 541-558.	1.7	92
25	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosomeâ€positive leukemias with the T315I mutation. Cancer, 2017, 123, 2875-2880.	2.0	79
26	Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. Journal of Clinical Oncology, 2016, 34, 501-508.	0.8	78
27	T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. British Journal of Haematology, 2001, 114, 624-631.	1.2	73
28	Managing pregnancy in chronic myeloid leukaemia. Annals of Hematology, 2015, 94, 167-176.	0.8	71
29	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, 23-26.	2.0	70
30	Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Haematologica, 2018, 103, 514-521.	1.7	70
31	Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. British Journal of Haematology, 2001, 115, 569-574.	1.2	66
32	RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia. Clinical Chemistry, 2017, 63, 525-531.	1.5	66
33	Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood, 2010, 116, 5497-5500.	0.6	65
34	Expert opinionâ€"management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia, 2020, 34, 1495-1502.	3.3	63
35	Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood, 2000, 96, 86-90.	0.6	62
36	CML in pregnancy and childhood. Best Practice and Research in Clinical Haematology, 2009, 22, 455-474.	0.7	62

#	Article	IF	Citations
37	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2365-2370.	2.0	61
38	Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood, 2010, 115, 4018-4020.	0.6	56
39	Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematology,the, 2020, 7, e50-e60.	2.2	53
40	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. Journal of Hematology and Oncology, 2018, 11, 143.	6.9	52
41	Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica, 2010, 95, 2126-2133.	1.7	51
42	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, S15-S18.	2.0	47
43	HLAâ€identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. British Journal of Haematology, 1992, 81, 383-390.	1.2	44
44	E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica, 2017, 102, e297-e299.	1.7	42
45	Allogeneic transplantation for CML in the TKI era: striking the right balance. Nature Reviews Clinical Oncology, 2016, 13, 79-91.	12.5	38
46	A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. British Journal of Haematology, 2020, 191, 171-193.	1.2	38
47	Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors. Haematologica, 2019, 104, 2400-2409.	1.7	37
48	Impact of route and adequacy of nutritional intake on outcomes ofÂallogeneic haematopoietic cell transplantation for haematologic malignancies. Clinical Nutrition, 2019, 38, 738-744.	2.3	37
49	Ruxolitinib for tocilizumabâ€refractory severe COVIDâ€19 infection. British Journal of Haematology, 2020, 190, e198-e200.	1.2	37
50	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. EBioMedicine, 2015, 2, 2101-2109.	2.7	36
51	BKVâ€specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLAâ€haploidentical haematopoietic cell transplantation. European Journal of Haematology, 2017, 98, 632-634.	1.1	36
52	Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients. Journal of Molecular Diagnostics, 2016, 18, 176-189.	1.2	34
53	The argument for using imatinib in CML. Hematology American Society of Hematology Education Program, 2018, 2018, 161-167.	0.9	34
54	A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial. Blood, 2012, 120, 163-163.	0.6	34

#	Article	IF	Citations
55	Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomolecular Detection and Quantification, 2017, 11, 4-20.	7.0	33
56	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood Cancer Discovery, 2020, 1, 48-67.	2.6	30
57	Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Therapeutic Advances in Hematology, 2020, 11, 204062072096612.	1.1	29
58	Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia. American Journal of Hematology, 1986, 22, 199-204.	2.0	27
59	Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 167-172.	0.6	27
60	Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation. Blood, 2011, 118, 109-109.	0.6	27
61	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Phâ€negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 778-785.	2.0	21
62	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation, 2019, 25, 2322-2329.	2.0	21
63	Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene, 2021, 40, 2697-2710.	2.6	20
64	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. Blood, 2020, 136, 51-52.	0.6	20
65	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	Article	IF	Citations
73	Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clinical Research in Cardiology, 2006, 95, 671-674.	1.5	14
74	Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: Innovation, automation, and harmonization. American Journal of Hematology, 2012, 87, 717-720.	2.0	14
75	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 131-142.	0.6	14
76	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2020, 55, 1763-1772.	1.3	14
77	Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2021, 11, 684659.	1.8	14
78	Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. Blood, 2008, 112, 3229-3229.	0.6	14
79	Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma. Cancer Gene Therapy, 2000, 7, 954-962.	2.2	13
80	Durable humoral responses after the second antiâ€SARSâ€CoVâ€2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. British Journal of Haematology, 2022, 197, .	1.2	13
81	Chronic Myeloid Leukemiaâ€“Transplantation in the Tyrosine Kinase Era. Hematology/Oncology Clinics of North America, 2014, 28, 1037-1053.	0.9	12
82	Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis. Blood, 2008, 112, 188-188.	0.6	12
83	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Biology of Blood and Marrow Transplantation, 2018, 24, 930-936.	2.0	11
84	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. Blood, 2019, 134, 498-498.	0.6	11
85	MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia. Haematologica, 2019, 104, 2206-2214.	1.7	10
86	Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality. Leukemia, 2020, 34, 667-670.	3.3	10
87	Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML. Blood, 2018, 132, 457-457.	0.6	10
88	Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing â‰¥ 3 Prior TKI Therapies: Initial Safety and Efficacy. Blood, 2019, 134, 4158-4158.	0.6	10
89	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.. Blood, 2009, 114, 3290-3290.	0.6	10
90	A Phase II Multicenter Trial of HSV-TK Engineered Donor Lymphocytes after Haplo-Identical HSCT: Early Immune Reconstitution and Abrogation of Gvhd.. Blood, 2004, 104, 436-436.	0.6	10

#	Article	IF	Citations
91	Managing the Patient with Chronic Myeloid Leukemia Through and After Allogeneic Stem Cell Transplantation. Hematology American Society of Hematology Education Program, 2006, 2006, 226-232.	0.9	9
92	Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.. Journal of Clinical Oncology, 2013, 31, 7048-7048.	0.8	9
93	Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrowand mobilised peripheral blood. European Journal of Haematology, 2000, 64, 85-92.	1.1	8
94	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. EClinicalMedicine, 2019, 15, 33-41.	3.2	8
95	Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq1 1 0.784314 rgBT	1.6	8
96	Dose Modification Dynamics of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) from the PACE and Optic Trials. Blood, 2021, 138, 2550-2550.	0.6	8
97	A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. Genome Medicine, 2015, 7, 128.	3.6	7
98	CML and tyrosine kinase inhibition: the hope becomes reality. Lancet Haematology,the, 2015, 2, e176-e177.	2.2	7
99	Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia. American Journal of Hematology, 2016, 91, E480-E481.	2.0	7
100	Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations. Haematologica, 2020, 105, e225-e227.	1.7	7
101	C-Reactive Protein on Admission Predicts Transplant-Related Mortality in Recipients of Allogeneic Stem Cell Transplant.. Blood, 2007, 110, 3005-3005.	0.6	7
102	Nilotinib Is Safe and Effective in Accelerated Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib Resistance or Intolerance.. Blood, 2007, 110, 471-471.	0.6	7
103	Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival. Blood, 2008, 112, 332-332.	0.6	7
104	Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. Blood, 2015, 126, 4024-4024.	0.6	7
105	Assessment of quantitative polymerase chain reaction for BCRâ€“ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact ofÂtechnology?. British Journal of Haematology, 2022, 197, 52-62.	1.2	7
106	Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. Haematologica, 2016, 101, 382-390.	1.7	6
107	Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Annals of Hematology, 2016, 95, 967-972.	0.8	6
108	Câ€reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of earlyâ€and longâ€term mortality. British Journal of Haematology, 2018, 180, 889-892.	1.2	6

#	Article	IF	Citations
109	Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13). American Journal of Hematology, 2021, 96, 163-164.	2.0	6
110	Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy. British Journal of Haematology, 2021, 192, 137-145.	1.2	6
111	Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.. Blood, 2010, 116, 3414-3414.	0.6	6
112	Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. Blood, 2012, 120, 3747-3747.	0.6	6
113	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. Blood, 2014, 124, 738-738.	0.6	6
114	For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.. Blood, 2007, 110, 323-323.	0.6	6
115	Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia. Blood, 2020, 136, 20-20.	0.6	6
116	Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling. Blood Cancer Journal, 2018, 8, 24.	2.8	5
117	What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?. Current Hematologic Malignancy Reports, 2019, 14, 477-479.	1.2	5
118	A Distinct Pattern of Non-HLA Polymorphisms Predicts an Increased Risk for GvHD without Benefit of GvL in HLA Matched Sibling Transplants for Chronic Myeloid Leukemia (CML).. Blood, 2006, 108, 54-54.	0.6	5
119	Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. Blood, 2012, 120, 3763-3763.	0.6	5
120	Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. Blood, 2016, 128, 938-938.	0.6	5
121	PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.. Journal of Clinical Oncology, 2012, 30, 6503-6503.	0.8	5
122	A Comparison of Stem Cell Source in Adult and Paediatric Recipients of T-Cell Depleted Myeloablative Transplants for Standard Risk Leukaemia: No Difference in Mortality Using BM or PBSC.. Blood, 2009, 114, 1205-1205.	0.6	5
123	Thyroid Function Abnormalities Associated with Ponatinib Therapy in Patients with Chronic Myeloid Leukemia. Thyroid, 2015, 25, 706-707.	2.4	4
124	Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia. Leukemia Research, 2016, 49, 47-50.	0.4	4
125	Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. Cancers, 2021, 13, 2155.	1.7	4
126	The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML). Blood, 2015, 126, 2795-2795.	0.6	4

#	Article	IF	Citations
127	Treatment of Steroid-Resistant Acute GvHD with OKT3 and High-Dose Steroids Versus High-Dose Steroids Alone.. Blood, 2005, 106, 141-141.	0.6	4
128	Optimizing Patient Selection for Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia.. Blood, 2009, 114, 3392-3392.	0.6	4
129	Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296. British Journal of Haematology, 1999, 107, 401-408.	1.2	3
130	Reducing the diversity of allogeneic transplant protocols in the UK through a BSBMT Anthony Nolan Protocol Harmonization Initiative. Bone Marrow Transplantation, 2020, 55, 1840-1843.	1.3	3
131	Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study. Blood, 2019, 134, 320-320.	0.6	3
132	A Randomized Singleâ^'Blind Study of Extracorporeal Photopheresis with UVADEXÂ® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.. Blood, 2006, 108, 758-758.	0.6	3
133	Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis.. Blood, 2007, 110, 2945-2945.	0.6	3
134	Assessment of Early Cytogenetic Response As a Predictor of Long-Term Clinical Outcomes in a Phase 1/2 Study of Bosutinib in Chronic Phase CML.. Blood, 2012, 120, 2798-2798.	0.6	3
135	Clinical Efficacy of BK Virus Specific T-Cells in Treatment of Severe Refractory Hemorrhagic Cystitis after HLA Haploidentical Transplantation. Blood, 2016, 128, 5726-5726.	0.6	3
136	Use of Direct Sequence PCR for ABl Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.. Blood, 2005, 106, 2002-2002.	0.6	3
137	The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia. Blood, 2016, 128, 5435-5435.	0.6	3
138	The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients. Leukemia and Lymphoma, 2019, 60, 3333-3334.	0.6	2
139	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 686-693.	0.2	2
140	Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients.. Blood, 2005, 106, 1804-1804.	0.6	2
141	Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.. Blood, 2007, 110, 1037-1037.	0.6	2
142	Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.. Blood, 2009, 114, 1229-1229.	0.6	2
143	The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.. Blood, 2010, 116, 3410-3410.	0.6	2
144	Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. Blood, 2012, 120, 3749-3749.	0.6	2

#	Article	IF	Citations
145	Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy. Blood, 2016, 128, 1223-1223.	0.6	2
146	Microbial Contamination of Haematopoietic Stem Cell Products: A Single Centre Experience. Blood, 2016, 128, 5741-5741.	0.6	2
147	Never say never again!. Blood, 2006, 108, 786-787.	0.6	1
148	Imatinibâ€"should we have more of a good thing?. Nature Reviews Clinical Oncology, 2010, 7, 303-304.	12.5	1
149	Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCRâ€"ABL1. Leukemia and Lymphoma, 2019, 60, 3090-3091.	0.6	1
150	Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis. Cancers, 2021, 13, 4863.	1.7	1
151	Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.. Blood, 2007, 110, 1045-1045.	0.6	1
152	Severe Donor Events after Allogeneic Hematopoietic Stem Cell Donation.. Blood, 2007, 110, 3276-3276.	0.6	1
153	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. Blood, 2010, 116, 2539-2539.	0.6	1
154	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Blood, 2016, 128, 2226-2226.	0.6	1
155	The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions. Blood, 2016, 128, 5987-5987.	0.6	1
156	Anti-Angiogenic Effect of Bortezomib in Multiple Myeloma Patients.. Blood, 2004, 104, 4912-4912.	0.6	1
157	Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs. Blood, 2010, 116, 2274-2274.	0.6	1
158	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. Blood, 2010, 116, 2348-2348.	0.6	1
159	Use Of a Quality Management System and Outcome After Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 2945-2945.	0.6	1
160	NF-Î°B-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib. Blood, 2019, 134, 2923-2923.	0.6	1
161	The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. British Journal of Haematology, 2022, , .	1.2	1
162	Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study. Leukemia and Lymphoma, 2022, , 1-4.	0.6	1

#	Article	IF	Citations
163	â€œStem cell transplantation: its importance todayâ€• Memo - Magazine of European Medical Oncology, 2012, 5, 277-280.	0.3	0
164	Evolution of Advanced Chronic Lymphoid Leukemia Unveiled by Single-Cell Transcriptomics: A Case Report. Frontiers in Oncology, 2020, 10, 584607.	1.3	0
165	An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets. British Journal of Haematology, 2020, 190, e236-e239.	1.2	0
166	Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood, 2000, 96, 2712-2716.	0.6	0
167	A Multi-Institutional Study of Extracorporeal Photoimmune Therapy with UVADEXÂ® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2004, 104, 1230-1230.	0.6	0
168	Long-Term Outcome after LACE (Lomustine, Ara-C, Cyclophosphamide, Etoposide) Conditioned Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkinâ€™s Lymphoma: A Single Centre Experience.. Blood, 2005, 106, 5502-5502.	0.6	0
169	Primary Plasma Cell Leukaemia and Autologous Stem Cell Transplantation.. Blood, 2007, 110, 731-731.	0.6	0
170	Association between the Polycomb Group (PcG) BMI-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell Transplantation (allo-SCT).. Blood, 2007, 110, 464-464.	0.6	0
171	Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era.. Blood, 2008, 112, 970-970.	0.6	0
172	Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia. Blood, 2008, 112, 3113-3113.	0.6	0
173	Incorporating Marrow Plasma Cell Infiltration at Diagnosis and Cytogenetic Features into Prognostic Scoring at Point of Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2008, 112, 3319-3319.	0.6	0
174	Ethnic Disparity in Access to Stem Cell Transplantation for Multiple Myeloma.. Blood, 2009, 114, 1781-1781.	0.6	0
175	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.. Blood, 2009, 114, 3248-3248.	0.6	0
176	The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure.. Blood, 2009, 114, 2147-2147.	0.6	0
177	Uptake and Outcome of Artificial Reproductive Techniques Following Allogeneic Stem Cell Tranplantation: A Single Centre Experience.. Blood, 2009, 114, 2257-2257.	0.6	0
178	T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.. Blood, 2009, 114, 2214-2214.	0.6	0
179	Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma.. Blood, 2009, 114, 2840-2840.	0.6	0
180	KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. Blood, 2010, 116, 888-888.	0.6	0

#	Article	IF	Citations
181	2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection. Blood, 2010, 116, 677-677.	0.6	0
182	Response to Tyrosine Kinase Inhibitor Therapy In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Phase Chronic Myeloid Leukemia. Blood, 2010, 116, 3515-3515.	0.6	0
183	A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. Blood, 2010, 116, 1697-1697.	0.6	0
184	Preconditioning Level of C-Reactive Protein and Disease Stage Are Key Prognostic Factors In Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2010, 116, 3488-3488.	0.6	0
185	DMSO Reduction Strategies Reduce DMSO Induced Post Autologous Transplant Morbidity In Patients with Lymphoma and Myeloma â€“Results from an EBMT Non Interventional Prospective Study. Blood, 2010, 116, 2397-2397.	0.6	0
186	Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,. Blood, 2011, 118, 4052-4052.	0.6	0
187	Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide. Blood, 2011, 118, 1932-1932.	0.6	0
188	Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 1945-1945.	0.6	0
189	Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma. Blood, 2012, 120, 4548-4548.	0.6	0
190	Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma. Blood, 2012, 120, 4554-4554.	0.6	0
191	A Novel Splice Site Variant of hOCT-1 and Response to Imatinib.. Blood, 2012, 120, 2555-2555.	0.6	0
192	Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party. Blood, 2013, 122, 4632-4632.	0.6	0
193	Clinical Outcome Following Change of Tyrosine Kinase Inhibitor (TKI) According to the Detection of an ABL Kinase Mutation. Blood, 2014, 124, 4557-4557.	0.6	0
194	MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/Î²-Catenin Interplay. Blood, 2014, 124, 4529-4529.	0.6	0
195	Androgen Function in Long-Term Survivors of Haematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3957-3957.	0.6	0
196	Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir-300 in Leukemic Stem/Progenitor Proliferation and Survival in CML. Blood, 2015, 126, 53-53.	0.6	0
197	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. Blood, 2016, 128, 3411-3411.	0.6	0
198	An Alternative Donor Is a Valid Option Compared to a Matched-Unrelated in Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in CR2: A Report of 841 Patients from the EBMT Acute Leukemia Working Party. Blood, 2016, 128, 3497-3497.	0.6	0

#	Article	IF	Citations
199	RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukaemia. Blood, 2016, 128, 3104-3104.	0.6	0
200	Manufacturing of Mesenchymal Stromal Cells for the Treatment of Graft-Versus-Host Disease: A Survey within the European Society of Blood and Marrow Transplantation. Blood, 2016, 128, 3374-3374.	0.6	0
201	DNA-Based Digital PCR for the Quantification of Residual Disease in CML â€" Sensitivity or Specificity?. Blood, 2018, 132, 1738-1738.	0.6	0
202	Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience. Blood, 2018, 132, 3417-3417.	0.6	0
203	Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP). Blood, 2021, 138, 3959-3959.	0.6	0
204	Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT. Blood, 2021, 138, 3954-3954.	0.6	0